Sign Out
Reports of overdoses with Oseltamivir have been received from clinical trials and during post-marketing experience. In the majority of cases reporting overdose, no adverse events were reported.
Adverse events reported following overdose were similar in nature and distribution to those observed with therapeutic doses of Oseltamivir, described in Adverse Reactions.
No specific antidote is known.
